Targeting old bottleneck reveals new anticancer drug strategy: Hot target SIRT2 regulates ribonucleotide reductase

www.sciencedaily.com

The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists have identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts.

  • 0 Likes

  • 0 Comments